Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. [electronic resource]
Producer: 20190611Description: 313-319 p. digitalISSN:- 1938-0674
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Cetuximab -- administration & dosage
- Class I Phosphatidylinositol 3-Kinases -- genetics
- Colorectal Neoplasms -- drug therapy
- Female
- Follow-Up Studies
- GTP Phosphohydrolases -- genetics
- Humans
- Irinotecan -- administration & dosage
- Liver Neoplasms -- drug therapy
- Male
- Membrane Proteins -- genetics
- Middle Aged
- Mutation
- Prognosis
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins p21(ras) -- genetics
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.